November 19, 2024
lev_facher_100
Addiction Reporter

Good morning! This is Lev Facher, STAT’s addiction reporter, subbing for Theresa. Let’s get to today’s news.

bird flu

H5N1 mutations could make it easier for virus to infect humans

Genomic analysis of a serious bird flu case in British Columbia brings worrisome news from north of the border: The virus has undergone mutational changes that could make it easier to infect humans. 

There’s still no evidence that the Canadian teenager, who remains in critical condition, has infected anyone else, my colleague Helen Branswell writes. But the case continues to garner attention for two reasons. First, it’s still unclear how the teen was infected, and while most human cases to date have been mild, this one is severe. 

More worrisome is the genetic mutation that may have helped the virus’ ability to attach to certain receptors in the human lung. “By no means is this Day 1 of a pandemic,” Scott Hensley, a professor of microbiology at the University of Pennsylvania’s Perelman School of Medicine, told Helen. “There’s no indication … of human-to-human spread, which is all good. But this is exactly the scenario that we fear.” Read more here


cancer

One explanation for rising pancreatic cancer cases in adults under 40

Younger adults have for years been diagnosed with cancer at progressively higher rates, a development that has alarmed and puzzled experts. Pancreatic cancer is no exception to that trend, my colleague Jonathan Wosen writes. But while this rise could reflect a true increase in the incidence of the deadly disease, a team led by researchers at Brigham and Women’s Hospital argues for a different explanation: Doctors are catching nonlethal cases they would have otherwise missed, a phenomenon known as overdiagnosis.

The research team looked back on data from 2001 to 2020 stored in U.S. Cancer Statistics, a database of cancer registries, for adults aged 15 to 39. They found that while the incidence of pancreatic cancer cases and surgery to remove tumors increased, most of the growth came from early-stage cancers. Notably, pancreatic cancer deaths didn’t rise, nor did late-stage disease. The findings, published on Monday in the journal Annals of Internal Medicine, don’t definitively answer why doctors are detecting more early-stage disease, though the authors suspect that physicians are catching cases via medical imaging. They add that unnecessary pancreatic surgery risks damaging the organ.


first opinion

Opinion: Whether he thinks so or not, RFK Jr. is an 'anti-vaxxer'

Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services could put a known distributor of health misinformation in charge of the nation’s public health infrastructure. And while he’s pledged not to take vaccines away from Americans who want them, he’s spent decades casting doubt on vaccines’ safety and weaponizing certain minority communities’ mistrust of the health system. 

Though he’s often given the more polite label of “vaccine skeptic,” his track record speaks for itself, Jonathan Berman, the author of the 2020 book “Anti-vaxxers: How to Challenge a Misinformed Movement,” writes in a new First Opinion for STAT. 

“If someone consistently opposes vaccination, promotes vaccine misinformation, and works to dismantle vaccine programs, then the label ‘anti-vaxxer’ fits, regardless of how they describe themselves,” Berman writes. Read more here



cardiovascular disease

AHA conference spotlights GLP-1s and new drugs that target lipoprotein(a) 

IMG_5910

Elizabeth Cooney for STAT

Between President-elect Trump’s return to power, the proliferation of GLP-1 medications, and promising trial data for two medications targeting a common risk factor for cardiovascular disease, there was no shortage of conversation topics at the American Heart Association’s conference in Chicago. 

One attention-getting presentation offered scientific details from the SUMMIT trial, which looked at tirzepatide versus placebo in 731 people who have heart failure with preserved ejection fraction, or HFpEF. The drug,sold as Mounjaro (diabetes) and Zepbound (obesity), lowered the risk of heart failure becoming worse or cardiovascular death occurring in adults with obesity.  

Separately, Eli Lilly and Silence Therapeutics both reported promising data on drug candidates meant to lower lipoprotein(a) levels, a promising development for a serious cardiovascular disease risk factor that isn’t impacted by statins, diet, or exercise. Read more here.


weight loss drugs

Opinion: The FDA's risky stance on GLP-1 compounding

The FDA is foregoing its public health obligations by allowing pharmacists to compound GLP-1 medications as an alternative to brand-name drugs like Wegovy or Ozempic, Scott Gottlieb, the agency’s former commissioner, writes in a new First Opinion for STAT. 

In many cases, GLP-1 drugs are being compounded in pharmacies that do not meet the FDA’s highest manufacturing safety standards, Gottlieb argues. And while the agency initially cited shortages in certain GLP medications as a reason it was allowing compounding to continue, those shortages have largely resolved. 

The FDA was never intended to use its discretion on compounding enforcement as a means of helping to lower drug prices, Gottlieb argues, and doing so could set a precedent that leaves the agency vulnerable to outside political pressure. Read more here.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • The vet, the cattle prod, and the ‘guttural wail,’ Texas Monthly
  • $500,000 pay, predictable hours: How dermatology became the ‘it’ job in medicine, Wall Street Journal
  • In first meeting of FDA’s digital health advisory committee, generative AI is up for debate, STAT
  • A.I. chatbots defeated doctors at diagnosing illness, New York Times
  • Hospitals and insurers are optimistic Republicans will extend ACA subsidies, STAT

Thanks for reading! More tomorrow — Lev